Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

577P - Updated analysis of phase I dose-escalation and dose cohort expansion studies of senaparib (IMP4297) in Chinese patients with advanced solid tumours

Date

17 Sep 2020

Session

E-Poster Display

Topics

Clinical Research

Tumour Site

Presenters

Binghe Xu

Citation

Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc271

Authors

B. Xu1, C. Junning2, H. Guo3, P. Zhang1, S. Yang1, Y. Zhou1, R. Zhang1, J. Dongmei2, W. Shen2, S. Zhang3, S. Cai4, Y.E. Tian4, C. Hsieh4, C. Xu4, N. Ma4, Y. Chen4, S. Yang4, S. Zhang4

Author affiliations

  • 1 Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 2 Medical Oncology, Shanghai Cancer Center Fudan University, 200032 - Shanghai/CN
  • 3 Medical Oncology, Nanjing Drum Tower Hospital, 210008 - Nanjing/CN
  • 4 Medical Department, Impact Therapeutics, 200135 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 577P

Background

Seneparib (previously known as IMP4297) is a novel oral PARP inhibitor which is 20-fold more potent than olaparib in vivo and showing strong antitumor activity in preclinical studies. This phase I study of senaparib is to evaluate PK, safety/tolerability and preliminary antitumor activity in patients with advanced solid tumours.

Methods

The primary objective was to evaluate the safety profile of senaparib given orally QD, including the identification of the maximum tolerated dose and the recommended phase II dose (RP2D). Dose escalation was guided by a modified Fibonacci sequence, starting at 2 mg/day, with a traditional 3+3 design. Dose expansion cohort was planned to start from the dose level in which efficacy was observed.

Results

As of Feb 29, 2020, 54 patients, including 34 BRCA mutation carriers, had been enrolled at 2-120 mg dose level. No DLT was observed. The most frequent treatment-related adverse events (TRAE) were anemia (48%), followed by leukopenia (41%), thrombocytopenia (26%), neutropenia (22%), nausea (22%) and fatigue (22%). Most of them were grade 1 or 2 in severity. Seven (13%) patients interrupted and 3 (6%) patients discontinued treatment due to AEs. Among 41 pts with at least one follow-up RECIST 1.1 assessment, 6 germline BRCA+ patients, 1 somatic BRCA+ patient and 2 BRCA- patients had PR, including one long-lasting PR over 9 months (BRCA+ ovarian cancer, 60mg). The overall ORR and DCR was 22% and 61% respectively. In 17 BRCA+ ovarian cancer patients, the ORR is 24% and DCR is 82%. An alternative dosing regimen of 50mg bid is ongoing to compare PK characteristic between QD and BID dosing.

Conclusions

We further confirmed senaparib is well-tolerated, with mild to moderate haematologic toxicity as the most frequent TRAEs and showed encouraging signs of clinical activity. The 100 mg orally QD was selected as the RP2D based on safety, pharmacokinetics and clinical activity.

Clinical trial identification

NCT03508011.

Editorial acknowledgement

Legal entity responsible for the study

IMPACT Therapeutics Inc.

Funding

IMPACT Therapeutics Inc.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.